葵花药业去库存致净利预降超80% 销售费一年压缩9亿毛利率三连降

Core Viewpoint - The performance of Kew Flower Pharmaceutical has significantly declined, with a projected net profit drop of over 80% for the first half of 2025 compared to the previous year [2][4]. Financial Performance - Kew Flower Pharmaceutical expects a net profit of 70 million to 85 million yuan for the first half of 2025, a decrease of 82.52% to 85.61% year-on-year [4]. - The company reported a net profit of 486 million yuan in the first half of 2024, down from 638 million yuan in the first half of 2023 [5][6]. - In Q1 2025, the company achieved a revenue of 663 million yuan, a decline of 56.30% year-on-year, with net profits dropping by 77.62% [4][5]. Factors Affecting Performance - The decline in performance is attributed to two main factors: inventory digestion in distribution channels and high raw material costs leading to a temporary decrease in gross profit margins [6][7]. - The company is actively managing channel inventories to control total shipments and reduce stock levels [6][7]. Sales and Marketing Strategy - Kew Flower Pharmaceutical's sales expenses dramatically decreased from 1.367 billion yuan in 2023 to 431 million yuan in 2024, a reduction of over 68% [10][11]. - The company previously spent a significant portion of its sales expenses on advertising and promotional activities, which accounted for about 80% of total sales expenses [12]. Historical Context - Founded in 1966, Kew Flower Pharmaceutical transformed from a struggling state-owned enterprise into a major pharmaceutical group under the leadership of Guan Yanbin [8][10]. - The company has faced challenges since the legal issues surrounding its founder in 2018, but has seen some recovery under the leadership of his daughters [9][10]. Industry Position - Kew Flower Pharmaceutical has a strong market presence in pediatric medicine, with over 60 products in its "Little Kew Flower" line, leading in sales scale and product quantity [10]. - The company's gross profit margin has been declining for three consecutive years, from 57.75% in 2022 to 44.89% in 2024 [13].